Skip to content

Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01125150
Enrollment
9
Registered
2010-05-18
Start date
2009-02-28
Completion date
2012-06-30
Last updated
2012-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acanthosis Nigricans, Hyperinsulinemia, Spectroscopic Analysis

Keywords

diffuse reflectance spectroscopy

Brief summary

Acanthosis Nigricans is skin disease that associated with hyperinsulinemia. Clinical is velvety hyperpigmented plaques on neck, axilla, groin. If hyperinsulinemia is improved by treated with oral metformin and/ or diet control, acanthosis nigricans would be improved as well. Hyperpigmented plaques will be changed. We assess objective measurement by using spectroscopic and colorimetric analysis.

Interventions

DRUGMetformin

Dosage to be determined by Endocrinologist

BEHAVIORALDietary Modification

To be determined by Endocrinologist

Sponsors

Henry Ford Health System
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
11 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Subjects must have an elevated fasting insulin level, suggesting they are in an insulin resistant state. 2. Subjects must carry a diagnosis of acanthosis nigricans, which will be verified by a Dermatologist before entry into the study. If necessary, a small 4mm punch biopsy may be taken to document dermatopathology consistent with acanthosis nigricans. 3. Subjects must be willing and able to undergo treatment with Metformin, including initial referral and follow up. 4. Agree to abide by the investigator's guidelines 5. Be able to understand the requirements of the study, the risks involved and are able to sign the informed consent form 6. Agree to follow and undergo all study-related procedures

Exclusion criteria

1. Subjects with Type 1 Diabetes are excluded because of their naturally insulin-deficient, rather than hyper-insulinemic, states. 2. Women who are lactating, pregnant, or planning to become pregnant. 3. Any reason the investigator feels the patient should not participate in the study. \-

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026